echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lenzilumab prevents or treats cytokine storms and neurotoxicity associated with CAR-T cell therapy

    Lenzilumab prevents or treats cytokine storms and neurotoxicity associated with CAR-T cell therapy

    • Last Update: 2021-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Humanigen, a clinical biopharmaceutical company, announced today that the U.S. Patent and Trademark Office has granted the company a patent for cytokine storms and neurotoxicity in patients treated with the chilayer antigen recipient T (CAR-T) cells using lenzilumab.
    patent covers the use of lenzilumab for the prevention or treatment of cytokine release syndrome (CRS) and neurotoxicity in patients treated with CAR-T cells.
    Lenzilumab is combined and mesothetic with granulocyte macrophage cluster stimulation factors (GM-CSF), which is considered a key factor in triggering toxic reactions associated with CAR-T cell therapy, such as CRS and neurotoxicity.
    Believe that lenzilumab may play an important role in enhancing CAR-T cell therapy, and we are committed to driving the development of lenzilumab to address cytokine storms associated with CAR-T cell therapy and other cytotherapy," said Cameron Durrant, M.D., M.D.
    patent emphasizes the pioneering approach to neutrality with GM-CSF with lenzilumab."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.